This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prostate Volume Changes Following Prostate Brachytherapy With Iodine-125 Seeds

This study has been completed.
Information provided by:
New York Methodist Hospital Identifier:
First received: July 3, 2006
Last updated: May 20, 2008
Last verified: May 2008
The size of the prostate changes due to insertion of the radioactive seeds. We will measure the prostate size, before and after the procedure.

Condition Intervention
Prostate Cancer Procedure: Brachytherapy with Iodine-125 seeds

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational Study to Evaluate the Changes in Prostate Volume Over Time With The Use of Transrectal Ultrasound and Computed Tomography Following Permanent Prostate Brachytherapy With Iodine-125 Seeds.

Resource links provided by NLM:

Further study details as provided by New York Methodist Hospital:

Enrollment: 29
Study Start Date: May 2006
Study Completion Date: March 2008
Intervention Details:
    Procedure: Brachytherapy with Iodine-125 seeds
    Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
    Other Name: Prostate Volume over time
Detailed Description:
The prostate size will be measured using the TRUS and CT scan on days -1, 0, 1, 9, 30, and 60 days after the brachytherapy procedure.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Prostate Cancer patients

Inclusion Criteria:

  • Pathologically confirmed diagnosis of prostate cancer
  • T1-3 disease
  • PSA <20 ng/ml
  • Patient must sign a study-specific informed consent prior to enrollment.

Exclusion Criteria:

  • Patients ineligible to brachytherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00348465

Sponsors and Collaborators
New York Methodist Hospital
Study Chair: Hani Ashamalla, MD, FCCP New York Methodist Hospital
Principal Investigator: Ewa Bieniek, MD NY Methodist Hospital
  More Information

Responsible Party: New York Methodist Hospital Identifier: NCT00348465     History of Changes
Other Study ID Numbers: NYM-353
Study First Received: July 3, 2006
Last Updated: May 20, 2008

Keywords provided by New York Methodist Hospital:
Prostate volume

Additional relevant MeSH terms:
Anti-Infective Agents, Local
Anti-Infective Agents
Trace Elements
Growth Substances
Physiological Effects of Drugs processed this record on September 19, 2017